Serum levels of omentin in end-stage renal disease patients

Kidney and Blood Pressure Research

Volumn 35, Issue 6, 2013, Pages 511-516

  Alcelik, Aytekin ^a   Tosun, Mehmet ^a   Ozlu, Mehmet Fatih ^a   Eroglu, Mustafa ^b   Aktas, Gulali ^a   Kemahli, Eray ^a   Savli, Haluk ^a   Yazici, Mehmet ^a  

^a Izzet Baysal Medical Faculty   (Turkey)

^b Oray Dialysis Center   (Turkey)

Author keywords

Diabetes mellitus; End stage renal disease; Hemodialysis; Omentin

Indexed keywords

CREATININE; OMENTIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; GPI-LINKED PROTEINS; HUMANS; KIDNEY FAILURE, CHRONIC; LECTINS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84863874363     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000338796     Document Type: Article

References (31)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112-S119.
2. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N, European Uremic Toxin Work Group: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056.
3. Akdag I, Yilmaz Y, Kahvecioglu S, Bolca N, Ercan I, Ersoy A, Gullulu M: Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with endstage renal disease: A 5-year prospective study. Nephron Clin Pract 2008; 108:C99-C105.
4. Coskun A, Bicik Z, Duran S, Alcelik A, Soypacaci Z, Yavuz O, Oksuz S: Pregnancyassociated plasma protein a in dialysis patients. Clin Chem Lab Med 2007; 45: 63-66.
5. Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y, Therapy JSD: Elevated nonhigh-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 1112-1120.
6. Tripepi G, Mattace Raso F, Sijbrands E, Seck MS, Maas R, Boger R, Witteman J, Rapisarda F, Malatino L, Mallamaci F, Zoccali C: Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol 2011; 6: 1714-1721.
7. Assadi M, Salimipour H, Akbarzadeh S, Nemati R, Jafari SM, Bargahi A, Samani Z, Seyedabadi M, Sanjdideh Z, Nabipour I: Correlation of circulating omentin-1 with bone mineral density in multiple sclerosis: The crosstalk between bone and adipose tissue. PloS One 2011; 6:e24240.
8. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernandez-Real JM: Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity 2011; 19: 1552-1559.
9. Tan BK, Adya R, Randeva HS: Omentin: A novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010; 20: 143-148.
10. Liu R, Wang XL, Bu PL: Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 2011; 93: 21-25.
11. Moreno-Navarrete JM, Catalan V, Ortega F, Gomez-Ambrosi J, Ricart W, Fruhbeck G, Fernandez-Real JM: Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010; 7: 27.
12. Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS: Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 2010; 59: 3023-3031.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment Y insulin resistance and beta-cell function from fasting plasmaglucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
14. Mathur S, Devaraj S, Jialal I: Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease. Curr Opin Nephrol Hypertens 2002; 11: 141-147.
15. Oberg BP, McMenamin E, Lucas FL, Mc-Monagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-1016.
16. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y: Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894-1900.
17. Zanetti M, Barazzoni R, Guarnieri G: Inflammation and insulin resistance in uremia. J Renal Nutr 2008; 18: 70-75.
18. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290:E1253-E1261.
19. Lago F, Dieguez C, Gomez-Reino J, Gualillo O: Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheum 2007; 3: 716-724.
20. Abdallah E, Waked E, Nabil M, El-Bendary O: Adiponectin and cardiovascular outcomes among hemodialysis patients. Kidney Blood Press Res 2012; 35: 247-253.
21. Axelsson J, Stenvinkel P: Role of fat mass and adipokines in chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 25-31.
22. Malyszko J, Malyszko JS, Mysliwiec M: Visfatin and endothelial function in dialyzed patients. Nephrology 2010; 15: 190-196.
23. Rao M, Li LJ, Tighiouart H, Jaber BL, Pereira BJG, Balakrishnan VS, HEMO Study Group: Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 2008; 23: 2619-2628.
24. Taskapan MC, Taskapan H, Sahin I, Keskin L, Atmaca H, Ozyalin F: Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modality. Ren Fail 2007; 29: 147-154.
25. Chudek J, Adamczak M, Karkoszka H, Budzinski G, Ignacy W, Funahashi T, Matsuzawa Y, Cierpka L, Kokot F, Wiecek A: Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003; 35: 2186-2189.
26. Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD: Adiponectin in peritoneal dialysis patients: A comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 2004; 43: 1047-1055.
27. Tsao YT, Hsu YJ, Chu NF, Lai CH, Chiu JS, Lin SH: Association of plasma adiponectin and cardiovascular risk profiles in nondiabetic uremic patients on peritoneal dialysis. J Nephrol 2008; 21: 744-752.
28. Brunzell JD, Hokanson JE: Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22(suppl 3):C10-C13.
29. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC: Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661.
30. Tan BK, Pua S, Syed F, Lewandowski KC, O'Hare JP, Randeva HS: Decreased plasma omentin-1 levels in type 1 diabetes mellitus. Diabet Med 2008; 25: 1254-1255.
31. Pan HY, Guo L, Li Q: Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010; 88: 29-33.